按WHO组织学分类的肺腺癌体积与质量倍增时间
回顾性纳入172例手术切除的浸润性肺腺癌患者(另有10例鳞状细胞癌作对照),用至少间隔84天的薄层平扫胸部CT进行三维半自动分割,计算体积倍增时间(VDT)和质量倍增时间(MDT)。结果显示肿瘤倍增时间因IASLC/ATS/ERS组织学分类而异,实性/微乳头亚型最短,VDT 465.2天和MDT 437.5天区分实性/微乳头亚型与其他腺癌亚型的AUC分别为0.791和0.795。
要点
- 实性/微乳头为主型腺癌中位VDT 232.7天、MDT 221.8天,生长最快。
- 贴壁为主型腺癌中位VDT 1140.6天、MDT 970.1天,生长最慢。
- VDT 465.2天区分实性/微乳头亚型与其他腺癌亚型AUC为0.791。
核心结论
- 浸润性肺腺癌的肿瘤倍增时间因IASLC/ATS/ERS组织学分类不同而异。
- 实性/微乳头为主型的体积和质量的调整特定生长率显著短于腺泡、贴壁和乳头为主型。
- 组织学亚型与肿瘤倍增时间独立相关。
研究设计与样本
- 回顾性研究,从2905例手术切除肺腺癌患者中纳入172例(平均年龄65.6±9.0岁),另纳入10例鳞状细胞癌(平均年龄70.9±7.4岁)作对照。
- 入组条件为有至少间隔84天、CT参数相同的配对薄层平扫胸部CT。
- 对结节行三维半自动分割,计算体积倍增时间(VDT)、质量倍增时间(MDT)及体积和质量的特定生长率(SGR)。
- 采用多变量线性回归、单因素方差分析和受试者工作特征曲线分析。
关键影像表现/征象
- 中位VDT和MDT分别为:腺泡型603.2天和639.5天,贴壁型1140.6天和970.1天,实性/微乳头型232.7天和221.8天,乳头型599.0天和624.3天,浸润性黏液型440.7天和438.2天,鳞状细胞癌149.1天和146.1天。
- 实性/微乳头为主型的体积和质量的调整SGR显著短于腺泡、贴壁和乳头为主型。
诊断标准与关键数值
- VDT阈值465.2天区分实性/微乳头为主型与其他肺腺癌亚型,AUC为0.791。
- MDT阈值437.5天区分实性/微乳头为主型与其他肺腺癌亚型,AUC为0.795。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to evaluate the tumor doubling time of invasive lung adenocarcinoma according to the International Association of the Study for Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) histologic classification.
MATERIALS AND METHODS: Among the 2905 patients with surgically resected lung adenocarcinoma, we retrospectively included 172 patients (mean age, 65.6 ± 9.0 years) who had paired thin-section non-contrast chest computed tomography (CT) scans at least 84 days apart with the same CT parameters, along with 10 patients with squamous cell carcinoma (mean age, 70.9 ± 7.4 years) for comparison. Three-dimensional semiautomatic segmentation of nodules was performed to calculate the volume doubling time (VDT), mass doubling time (MDT), and specific growth rate (SGR) of volume and mass. Multivariate linear regression, one-way analysis of variance, and receiver operating characteristic curve analyses were performed.
RESULTS: The median VDT and MDT of lung cancers were as follows: acinar, 603.2 and 639.5 days; lepidic, 1140.6 and 970.1 days; solid/micropapillary, 232.7 and 221.8 days; papillary, 599.0 and 624.3 days; invasive mucinous, 440.7 and 438.2 days; and squamous cell carcinoma, 149.1 and 146.1 days, respectively. The adjusted SGR of volume and mass of the solid-/micropapillary-predominant subtypes were significantly shorter than those of the acinar-, lepidic-, and papillary-predominant subtypes. The histologic subtype was independently associated with tumor doubling time. A VDT of 465.2 days and an MDT of 437.5 days yielded areas under the curve of 0.791 and 0.795, respectively, for distinguishing solid-/micropapillary-predominant subtypes from other subtypes of lung adenocarcinoma.
CONCLUSION: The tumor doubling time of invasive lung adenocarcinoma differed according to the IASCL/ATS/ERS histologic classification.
引用
- Hong JH, Park S, Kim H, et al. Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification. Korean J Radiol. 2020. PMID: 33169551. doi:10.3348/kjr.2020.0592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。